#Class Action #Wolf Haldenstein #DexCom

Urgent Call to DexCom Shareholders: Join the Class Action Lawsuit

Investors who have experienced losses from their DexCom, Inc. (NASDAQ: DXCM) shares are urged to act quickly as a class action lawsuit has been initiated against the company. This legal action, filed by the reputable firm Wolf Haldenstein Adler Freeman & Herz LLP, highlights critical failures in the company's disclosure practices regarding the safety and reliability of its continuous glucose monitoring devices, specifically the G6 and G7 models.

Allegations Against DexCom, Inc.

The lawsuit claims that DexCom and certain executives made false and misleading statements and omitted significant information that investors needed to make informed decisions. Most notably, the company reportedly made unauthorized modifications to the G6 and G7 devices without prior approval from the U.S. Food and Drug Administration (FDA). These alterations allegedly resulted in diminished reliability and posed potential health risks to users, a fact that was not communicated adequately to stakeholders.

Essential Facts About the Class Period

The allegations center on investor activities during the period from July 26, 2024, to September 17, 2025. Throughout this class period, DexCom is accused of overstating the reliability and functionality of its products while downplaying serious concerns about device accuracy and safety. Such misrepresentation has left many investors facing significant financial distress.

Key Events Impacting Stock Performance

Several events during this timeframe dramatically affected DexCom's stock price:

• - March 10, 2025: Following an FDA Warning Letter that labeled the G6 and G7 systems as